Naurex Initiates Phase I Clinical Trial For GLYX-13
Naurex has initiated a Phase I clinical trial of its GLYX-13 and has successfully dosed the first subjects in the study. GLYX-13, a glycine site functional partial agonist
Rocket Pharmaceuticals has entered into a credit facility agreement of up to $150m with Hercules Capital to support the ongoing development of its cardiovascular portfolio.
Makefield Therapeutics has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield’s biodegradable Hybrid Nanoparticles, a new drug delivery
Neptune Technologies & Bioressources (Neptune) announces additional preclinical research results on its Acasti Pharma (Acasti) drug development program. Acasti announces the results of additional preclinical research designed to
Unilife Medical Solutions (Unilife) has signed agreements for the construction of its new global headquarters and commercial production facility in York, Pennsylvania. The medical device production facility will
Advanced Life Sciences has reported positive top-line results from a pivotal, non-human primate study of its once-a-day, oral antibiotic Restanza (cethromycin) against an inhaled lethal dose of Tularemia.